Skeletal disorders associated with fibroblast growth factor receptor mutations

Current Opinion in Genetics and Development

Volumn 7, Issue 3, 1997, Pages 378-385

  De Moerlooze, Laurence ^a   Dickson, Clive ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR; PHOSPHOTRANSFERASE;

AUTOSOMAL DOMINANT INHERITANCE; BONE DISEASE; CRANIOFACIAL SYNOSTOSIS; DWARFISM; EMBRYO PATTERN FORMATION; ENZYME ACTIVATION; GENE MUTATION; HUMAN; PRIORITY JOURNAL; RECEPTOR GENE; REVIEW;

EID: 0030861090     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(97)80152-9     Document Type: Article

References (68)

1. Wilkie AOM, Morrisskay GM, Jones EY, Heath JK: Functions of fibroblast growth-factors and their receptors. Curr Biol 1995, 5:500-507.
2. Muenke M, Schell U: Fibroblast-growth-factor receptor mutations in human skeletal disorders. Trends Genet 1995, 11:308-313.
3. Yamaguchi TP, Rossant J: Fibroblast growth-factors in mammalian development. Curr Opin Genet Dev 1995, 5:485-491.
4. Park W-J, Bellus G, Jabs E: Mutations in fibroblast growth factor receptors: phenotypic consequences during eukaryotic development. Am J Hum Genet 1995, 57:748-754.
5. Johnson D, Williams L: Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 1993, 60:1-41.
6. Mason IJ: The ins and outs of fibroblast growth-factors. Cell 1994, 78:547-552.
7. Green PJ, Walsh FS, Doherty P: Promiscuity of fibroblast growth-factor receptors. Bioessays 1996, 18:639-646.
8. Basilico C, Moscatelli D: The FGF family of growth-factors and oncogenes. Adv Cancer Res 1992, 59:115-165.
9. Yamasaki M, Miyake A, Tagashira S, Itoh N: Structure and expression of the rat mRNA encoding a novel member of the fibroblast growth factor family. J Biol Chem 1996, 271:15918-15921.
10. Spivak-Kroizman T, Lemmon MA, Dikic I, Ladbury JE, Pinchasi D, Huang J, Jaye M, Crumley G, Schlessinger J, Lax I: Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell-proliferation. Cell 1994, 79:1015-1024.
11. Ornitz DM, Leder P: Ligand specificity and heparin dependence of fibroblast growth-factor receptor-1 and receptor-3. J Biol Chem 1992, 267:16305-16311.
12. Ornitz DM, Herr AB, Nilsson M, Westman J, Svahn CM, Waksman G: FGF binding and FGF receptor activation by synthetic heparan-derived disaccharides and trisaccharides. Science 1995, 268:432-436.
13. Ornitz DM, Xu JS, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao GX, Goldfarb M: Receptor specificity of the fibroblast growth-factor family. J Biol Chem 1996, 271:15292-15297.
14. Burgess W, Maciag T: The heparin binding (fibroblast) growth factor family proteins. Annu Rev Biochem 1989, 58:575-606.
15. Shiang R, Thompson LM, Zhu YZ, Church DM, Fielder TJ, Bocian M, Winokur ST, Wasmuth JJ: Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 1994, 78:335-342.
16. Rousseau F, Bonaventure J, Legeai ML, Pelet A, Rozet JM, Maroteaux P, Le MM, Munnich A: Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 1994, 371:252-254.
17. Tavormina PL, Shiang R, Thompson LM, Zhu YZ, Wilkin DJ, Lachman RS, Wilcox WR, Rimoin DL, Cohn DH, Wasmuth JJ: Thanatophoric dysplasia (type-I and type-II) caused by distinct mutations in fibroblast growth-factor receptor-3. Nat Genet 1995, 9:321-328.
18. Rousseau F, Saugier P, Le Merrer M, Munnich A, Delezoide A-L, Martoteaux P, Bonaventure J, Narcy F, Sanak M: Stop codon FGFR3 mutations in thanatophoric dwarfism type 1. Nat Genet 1995, 10:11-12.
19. Rousseau F, Elghouzzi V, Delezoide AL, Legeaimallet L, Lemerrer M, Munnich A, Bonaventure J: Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type-1 (td1). Hum Mol Genet 1996, 5:509-512.
20. Tavormina PL, Rimoin DL, Cohn DH, Zhu YZ, Shiang R, Wasmuth JJ: Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type-1. Hum Mol Genet 1995, 4:2175-2177.
21. Bellus GA, McIntosh I, Smith EA, Aylsworth AS, Kaitila I, Horton WA, Greenhaw GA, Hecht JT, Francomano CA: A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat Genet 1995, 10:357-359.
22. Rousseau F, Bonaventure J, Legeai-Mallet L, Schmidt H, Weissenbach J, Maroteaux P, Munnich A, Le Merrer M: Clinical and genetic heterogeneity of hypochodroplasia. J Med Genet 1996, 33:749-752.
23. Prinos P, Costa T, Sommer A, Kilpatrick M, Tsipouras P: A common FGFR3 gene mutation in hypochondroplasia. Hum Mol Genet 1995, 4:2097-2101.
24. Webster MK, Donoghue DJ: Constitutive activation of fibroblast growth-factor receptor-3 by the transmembrane domain point mutation found in achondroplasia. EMBO J 1996, 15:520-527. The achondroplasia mutation, as well as several other possible substitutions at the same or an adjacent site, shows constitutive activation of the receptor kinase. There is a correlation between the capacity to participate in hydrogen bond formation and kinase activation.
25. Naski MC, Wang Q, Xu JS, Ornitz DM: Graded activation of fibroblast growth-factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 1996, 13:233-237. This paper shows that the achondroplasia and TD mutations result in constitutive activation of the FGFR3 receptor kinase. They also demonstrate that the receptor kinase activity may or may not retain ligand responsiveness depending on the mutation; there is an approximate correlation between the level of kinase activation and the severity of the phenotype.
26. Neilson KM, Friesel R: Ligand-independent activation of fibroblast growth-factor receptors by point mutations in the extracellular, transmembrane, and kinase domains. J Biol Chem 1996, 271:25049-25057. An examination of the biochemical and functional consequences of several FGF receptor mutations identified in inherited chondrodysplasias and craniosynostosis syndromes. The mutations have been transposed to the highly homologous Xenopus FGFR1 and FGFR2 cDNAs and the effects on cellular tyrosine phosphorylation, receptor autophosphorylation and mesoderm induction in animal caps have been assessed. All but one of the mutations scored positive in these assays
27. Webster MK, Davis PY, Robertson SC, Donoghue DJ: Profound ligand-independent kinase activation of fibroblast growth-factor receptor-3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type-II. Mol Cell Biol 1996, 16:4081-4087.
28. Bargmann C, Hung M, Weinberg R: Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986, 45:649-657.
29. Sternberg M, Gullick W: Neu receptor dimerization. Nature 1989, 339:587.
30. Peters K, Ornitz D, Werner S, Williams L: Unique expression pattern of the fgf receptor-3 gene during mouse organogenesis. Dev Biol 1993, 155:423-430.
31. Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM: Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet 1996, 12:390-397. See annotation [32•].
32. Deng C, Wynshaw BA, Zhou F, Kuo A, Leder P: Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 1996, 84:911-921. These two papers [31•,32•] show that mice deficient for FGFR3 exhibit prolonged endochondral bone growth which causes skeletal abnormalities such as disproportionately extended limbs. These findings together with histological evidence demonstrate a role for FGFR3 as a negative regulator of endochondral ossification. This work provides a conceptual framework for understanding the consequences of inappropriate FGFR3 activation found in various chondrodysplasias.
33. Przylepa KA, Paznekas W, Zhang MH, Golabi M, Bias W, Bamshad MJ, Carey JC, Hall BD, Stevenson R, Orlow SJ et al.: Fibroblast growth-factor receptor-2 mutations in Beare-Stevenson Cutis Gyrata syndrome. Nat Genet 1996, 13:492-494.
34. Meyers GA, Orlow SJ, Munro IR, Przylepa KA, Jabs EW: Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans. Nat Genet 1995, 11:462-464.
35. Wilkes D, Rutland P, Pulleyn U, Reardon W, Moss C, Ellis JP, Winter RM, Malcolm S: A recurrent mutation, ala391glu, in the transmembrane region of FGFR3 causes crouzon syndrome and acanthosis nigricans. J Med Genet 1996, 33:744-748.
36. Chellaiah AT, McEwen DG, Werner S, Xu JS, Ornitz DM: Fibroblast growth-factor receptor (FGFR)-3 - alternative splicing in immunoglobulin-like domain-III creates a receptor highly specific for acidic FGF FGF-1. J Biol Chem 1994, 269:11620-11627.
37. Orr-Urtreger A, Bedford M, Burakova T, Arman E, Zimmer Y, Yayon A, Givol D, Lonai P: Developmental localization of the splicing alternatives of fibroblast growth-factor receptor-2 (FGFR2). Dev Biol 1993, 158:475-486.
38. Werner S, Weinberg W, Liao X, Peters K, Blessing M, Yuspa S, Weiner R, Williams L: Targeted expression of a dominant-negative FGF receptor mutant in the epidermis of transgenic mice reveals a role of FGF in keratinocyte organization and differentiation. EMBO J 1993, 12:2635-2643.
39. Zimmer Y, Givol D, Yayon A: Multiple structural elements determine ligand-binding of fibroblast growth-factor receptors-evidence that both Ig domain-2 and domain-3 define receptor specificity. J Biol Chem 1993, 268:7899-7903.
40. Cheon HG, Larochelle WJ, Bottaro DP, Burgess WH, Aaronson SA: High-affinity binding-sites for related fibroblast growth-factor ligands reside within different receptor immunoglobulin-like domains. Proc Natl Acad Sci USA 1994, 91:989-993.
41. Peters K, Werner S, Chen G, Williams L: Two FGF receptor genes are differentially expressed in epithelial and mesenchymal tissues during limb formation and organogenesis in the mouse. Development 1992, 114:233-243.
42. Neilson K, Friesel R: Constitutive activation of fibroblast growth factor receptor-2 by a point mutation associated with Crouzon syndrome. J Biol Chem 1995, 270:26037-26040. This is the first report of constitutive receptor activation caused by a mutation found in a Crouzon syndrome patient. This paper describes the effect of the FGFR2 mutation in a mesoderm induction assay using Xenopus animal caps. Induction of mesoderm in the absence of ligand indicates that the mutation causes a constitutive activation of the receptor.
43. Galvin BD, Hart KC, Meyer AN, Webster MK, Donoghue DJ: Constitutive receptor activation by crouzon syndrome mutations in fibroblast growth-factor receptor (FGFR)-2 and FGFR2/neu chimeras. Proc Natl Acad Sci USA 1996, 93:7894-7899. A number of different mutations found in Crouzon patient genomic DNAs were tested using FGFR-Neu receptor chimeras. Introduction of chimeric receptors containing the mutant extracellular domains of FGFR2 linked to the kinase domain of the Neu receptor resulted in a ligand-independent activation of the Neu receptor kinase and transformation of the recipient assay cells. All the mutations tested caused the activation of the receptor kinase, suggesting a common mechanism for this and similar craniosynostosis syndromes.
44. Bellus G, Gaudenz K, Zackai E, Clarke L, Szabo J, Francomano C, Muenke M: Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes. Nat Genet 1996, 14:174-176.
45. Schell U, Hehr A, Feldman G, Robin N, Zackai E, De Die-Smulders C, Viskochil M, Stewart J, Wolff G, Ohashi H et al.: Mutations in FGFR1 and FGFR2 cause familial and sporadic Pfeiffer syndrome. Hum Mol Genet 1995, 4:323-328.
46. White RA, Dowler LL, Angeloni SV, Pasztor LM, MacArthur CA: Assignment of FGF8 to human-chromosome 10q25-q26 - mutations in FGF8 may be responsible for some types of acrocephalosyndactyly linked to this region. Genomics 1995, 30:109-111.
47. Howard T, Paznekas W, Green E, Chiang L, Ma N, Ortiz De Luna R, Delado C, Gonzalez-Ramos M, Kline A, Jabs E: Mutations in TWIST, a basic helix-loop-helix transcription factor, in Saethre-Chotzen syndrome. Nat Genet 1997, 15:36-41. See annotation [48•].
48. Ghouzzi V, Le Merrer M, Perrin-Schmitt F, Lajeunie E, Benit P, Renier D, Bourgoeis P, Bolacto-Bellemin A-L, Munnich A, Bonaventure J: Mutations of the TWIST gene in the Saethre-Chotzen syndrome. Nat Genet 1997, 15:42-44. These two papers [47•,48•] describe the identification of a helix-loop-helix transcription factor as the cause of another syndrome involving craniosynostosis and limb abnormalities. The role of this factor in Drosophila and mice hint that it may be involved upstream of FGF/FGFR signalling in bone development.
49. Shishido E, Higashijima S, Emori Y, Saigo K: Two FGF-receptor homologues of Drosophila: one expressed in mesoderm primordium in early embryos. Development 1993, 117:751-761.
50. Chen Z, Behringer R: twist is required in head mesenchyme for cranial neural tube morphogenesis. Genes Dev 1995, 9:686-699.
51. Jabs EW, Li X, Scott AF, Meyers G, Chen W, Eccles M, Mao JI, Charnas LR, Jackson CE, Jaye M: Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2 [published erratum appears in Nat Genet 1995, 9:451]. Nat Genet 1994, 8:275-279.
52. Park WJ, Meyers GA, Li X, Theda C, Day D, Orlow SJ, Jones MC, Jabs EW: Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show allelic heterogeneity and phenotypic variability. Hum Mol Genet 1995, 4:1229-1233.
53. Park WJ, Theda C, Maestri NE, Meyers GA, Fryburg JS, Dufresne C, Cohen MJ, Jabs EW: Analysis of phenotypic features and FGFR2 mutations in Apert syndrome. Am J Hum Genet 1995, 57:321-328.
54. Reardon W, Winter R, Rutland P, Pulleyn L, Jones B, Malcolm S: Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nat Genet 1994, 8:98-103.
55. Muenke M, Schell U, Hehr A, Robin N, Losken H, Schinzel A, Pulleyn L, Rutland P, Reardon W, Malcolm S, Winter R: A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome. Nat Genet 1994, 8:269-274.
56. Oldridge M, Wilkie AOM, Slaney SF, Poole MD, Pulleyn LJ, Rutland P, Hockley AD, Wake MJ, Goldin JH, Winter RM et al.: Mutations in the third immunoglobulin domain of the fibroblast growth factor receptor-2 gene in Crouzon syndrome. Hum Mol Genet 1995, 4:1077-1082.
57. Wilkie AO, Slaney SF, Oldridge M, Poole MD, Ashworth GJ, Hockley AD, Hayward RD, David DJ, Pulleyn LJ, Rutland P et al.: Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome [see comments]. Nat Genet 1995, 9:165-172.
58. Lajeunie E, Ma HW, Bonaventure J, Munnich A, Le Merrer M, Renier D: FGFR2 mutations in Pfeiffer syndrome. Nat Genet 1995, 9:108.
59. Meyers GA, Day D, Goldberg R, Daentl DL, Przylepa KA, Abrams LJ, Graham JJ, Feingold M, Moeschler JB, Rawnsley E et al.: FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and Pfeiffer syndromes: evidence for missense changes, insertions, and a deletion due to alternative RNA splicing. Am J Hum Genet 1996, 58:491-498.
60. Gorry M, Preston R, White G, Zhang Y, Singhai V, Losken H, Parker M, Nwokoro N, Post J, Ehrlich G: Crouzon syndrome: mutations in two spliceoforms of FGFR2 and a common point mutation shared with Jackson-Weiss syndrome. Hum Mol Genet 1995, 4:1387-1390.
61. Rutland P, Pulleyn L, Reardon W, Baraitser M, Hayward R, Jones B, Malcolm S, Winter R, Oldridge M, Slaney S et al.: Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes. Nat Genet 1995, 9:173-176.
62. Oldridge M, Lunt P, Zackai E, McDonald-McGinn D, Muenke M, Moloney D, Twigg S, Heath J, Howard T, Hoganson G et al.: Genotype-phenotype correlation for nucleotide substitutions in the IgII-IgIII linker of FGFR2. Hum Mol Genet 1997, 6:137-143.
63. Steinberger D, Mulliken J, Muller U: Crouzon syndrome: previously unrecognized deletion, duplication, and point mutation within FGFR2 gene. Hum Mutat 1996, 8:386-390.
64. Steinberger D, Reinhartz T, Unsold R, Muller U: FGFR2 mutation in clinically nonclassifiable autosomal dominant craniosynostosis with pronounced phenotypic variation. Am J Med Genet 1996, 66:81-86.
65. Superti-Furga A, Eich G, Bucher H, Wisser J, Giedion A, Gitzelmann R, Steinmann B: A glycine 375-to-cysteine Substitution in the transmembrane domain of the fibroblast growth factor receptor-3 in a newborn with achondroplasia. Eur J Pediatr 1995, 1545:215-219.
66. Pulleyn L, Reardon W, Wilkes D, Rutland P, Jones B, Hayward R, Hall C, Brueton L, Chun N, Lammer E et al.: Spectrum of craniosynostosis phenotypes associated with novel mutations at the fibroblast growth factor receptor 2 locus. Eur J Genet 1996, 4:283-291.
67. Ikegawa S, Fukushima Y, Isomura M, Takada F, Nakamura Y: Mutations of the fibroblast growth factor receptor-3 gene in one familial and six sporadic cases of achondroplasia in Japanese patients. Hum Genet 1995, 96:309-311.
68. Li X, Park WJ, Pyeritz RE, Jabs EW: Effect on splicing of a silent FGFR2 mutation in Crouzon syndrome [letter]. Nat Genet 1995, 9:232-233.